Candel Therapeutics Inc
Research Candel Therapeutics Inc (CADL) on Bullrun: market cap USD 759.08M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCADL
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 759.08M
- Financial periodFY2025
- Net income-USD 38.18M
- Free cash flow-USD 38.90M
Valuation Snapshot
latest market cap is USD 759.08M.
About Candel Therapeutics Inc
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma.
Frequently asked questions
What is Candel Therapeutics Inc's market cap?
Candel Therapeutics Inc's market capitalization is USD 759.08M.
What does Candel Therapeutics Inc do?
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC).